Results: After the 3-month intervention, the serum 25(OH)D concentration in group A was significantly increased from 16.01±5.0 to 20.02±4.5 ng/mL, while that in group B had no significant change. The serum calcium levels in both the groups were significantly increased (group A: from 2.36±0.1 to 2.45±0.1 mmol/L; group B: from 2.36±0.1 to 2.44±0.1 mmol/L). The levels of serum intact parathyroid hormone in both the groups were significantly decreased (group A: from 48.56±12.8 to 39.59±12.6 pg/mL; group B: from 53.67±20.0 to 40.32±15.4 pg/mL). The serum levels of β-CTX in both the groups were also significantly decreased ( 
Introduction
The vitamin D receptor is found in bone, most tissues and cells in the body. Vitamin D deficiency is a common health problem that increases the risk of many common and serious diseases, including some cancers, type 1 diabetes, cardiovascular disease, and osteoporosis [1] . Vitamin D is important for maintaining bone health because it stimulates the synthesis of osteopontin and alkaline phosphatase and inhibits osteoblast apoptosis [2] . Vitamin D status is best evaluated by measuring the serum concentration of 25-hydroxyvitamin D [25(OH)D] [3] . Most specialties define vitamin D deficiency as 25(OH)D levels below 20 ng/mL [4] . A level of 25(OH)D of 21-29 ng/mL indicates a vitamin D insufficiency whereas a level of 30 ng/mL or greater indicates vitamin D sufficiency [5] . The prevalence of atrophic skin changes in older adults is concomitant with an increased probability of lower 25(OH)D levels [6] . Unlike those of other nutrients, dietary sources of vitamin D are limited. Therefore, most people require supplements such as cholecalciferol (vitamin D 3 ) to meet the recommended intake [7] . Current guidelines for vitamin D intakes vary around the world.
The National Osteoporosis Foundation (NOF) recommends an intake of 800 to 1000 international units (IU) of vitamin D per day for adults 50 years and older [8] . Hanley et al [9] have suggested that adults over 50 years old are at a moderate risk for vitamin D deficiency and recommended the use of a supplement with at least 800-1000 IU of vitamin D 3 . In an expert roundtable discussion, it was agreed that the daily vitamin D intake should be approximately 800 IU for most postmenopausal women [10] . One study indicated that serum 25(OH)D increased with cholecalciferol supplementation and nearly plateaued after 3-4 months of intervention [11] . In elderly people, diminished renal function due to aging leads to a decrease in renal conversion to 1,25(OH) 2 D 3 [12] . Calcitriol [1, 25(OH) 2 D 3 ] plays an important role in promoting bone formation, and D-hormone analogs prevent falls to a greater extent than does ordinary vitamin D. Therefore, the use of D-hormone analogs has been advocated for the treatment of osteoporosis in many studies [13] [14] [15] . Because patients who are treated with 0.5 μg/d or 1.0 μg/d of calcitriol tend to develop hypercalcinuria, serum and urinary calcium levels should be examined regularly, and the calcitriol regime should be examined intermittently. Patients are frequently treated with 0.25 μg/d of calcitriol in China, especially elderly patients with osteoporosis. Hurst et al [16] concluded that correcting vitamin D deficiency in older women may suppress the age-induced acceleration in bone turnover and may reduce bone resorption. However, Seemans et al [17] observed that despite the stratification of different vitamin D receptor genotypes, cholecalciferol supplementation throughout the winter months did not affect bone turnover markers in young or old people. The aim of the current study was to compare the effects of cholecalciferol at 800 IU per day and calcitriol at 0.25 μg per day on calcium metabolism and bone turnover in Chinese postmenopausal women who are vitamin D insufficient.
Materials and methods

Subjects and study design
This was an open-label, controlled clinical trial. The study was approved by the Ethics Committee of the Shanghai Jiao Tong University Affiliated Sixth People's Hospital.
One hundred healthy, independent, ambulatory, postmenopausal female volunteers were recruited from community centers. All participants were of Han ethnicity and had lived in Shanghai for more than 30 years. Postmenopausal women over 50 years of age were eligible for the study, and the serum 25(OH)D concentrations of all subjects were less than 30 ng/mL. All subjects were given a physical examination and were found to be in good health. No participant was receiving treatment or had medical complications that were known to affect bone metabolism, including hyperthyroidism, diabetes mellitus, primary hyperparathyroidism, renal failure, pituitary diseases, and adrenal diseases. All the women had taken less than 600 mg/day of calcium and less than 600 IU/day of vitamin D within the 3 months prior to enrollment. The subjects were divided into two groups based on age and serum 25 
Laboratory tests
Fasting blood samples were obtained at baseline and at the end of the study. Blood routine, erythrosedimentation, liver function, renal function and fasting blood-glucose were examined to exclude subjects who had other factors that may affect their vitamin D status. Markers of calcium metabolism and bone turnover were assessed before and after the three-month intervention, including serum calcium (Ca), phosphorus (P), alkaline phosphatase (AKP) (using the HITACHI7600-020 automatic biochemistry analyzer), intact parathyroid hormone (normal, 15-65 pg/mL, intact PTH Kit, Roche Diagnostics, Mannheim, Switzerland), concentrations of 25(OH)D (25 hydroxy vitamin D3 Kit, Roche Diagnostics, Mannheim, Switzerland; using a Cobase 6000 electrochemiluminescence analyzer) and β-CrossLaps of type I collagen containing crosslinked C-telopeptide (β-CTX) (β-CrossLaps Kit, Roche Diagnostics, Mannheim, Switzerland). The coefficients of variability (CV) of serum Ca, P, AKP, PTH, 25(OH)D, and β-CTX were 2.4%, 3.3%, 5.1%, 9.5%, 4.0%, and 3.4%, respectively.
Statistical analysis Data are represented as the mean±standard deviation (SD).
Comparisons of the result before and after treatments were calculated using paired Student's t-test for the parametric data of each group. The independent sample t-tests were used to compare the serum parameters before and after the treatments of groups A and B, respectively. The independent sample t-test was used to compare the difference in the change pattern over time between group A and group B, starting at the treatment baseline. All calculations were performed using SPSS ver 11.0 software (SPSS Inc, Chicago, IL, USA). Data were considered statistically significant at a value of P<0.05.
Results
The baseline characteristics of 100 postmenopausal women are shown in Table 1 . The mean age of the subjects was 63.8±7.0 years old, the mean menopausal period was 13.7±8.7 years, and the mean 25(OH)D level was 16.84±5.4 ng/mL.
Serum parameters of groups A and B
The baseline characteristics showed no differences between the two groups, except that β-CTX was significantly higher in group B than that in group A (P<0.05) ( Table 2) . After the three-month intervention, both groups showed a significant increase in serum Ca levels (all P<0.01) that were within the normal range. The AKP levels of groups A and B also showed a significant increase (P<0.05 and P<0.01, respectively). The serum PTH and β-CTX levels showed a significant decrease in both groups (all P<0.01 and all P<0.05) ( Table 3) .
We compared the serum parameters between the two groups after the 3-month intervention and identified significantly higher levels of serum 25(OH)D in group A than those of group B (P<0.01) ( Table 4) . We compared the difference in Values shown in boldface are statistically significant. (Table 5) .
Withdrawal from the study and adverse events Eight participants (5 participants in the group A and 3 participants in the group B) discontinued the study. In the group A, two participants withdrew without providing a reason, two participants were lost during follow-up, and one participant withdrew because of cholelithiasis and shingles that, according to the clinical judgment, were attributed to a severe adverse event but were not related to the use of study medication. In the group B, three participants withdrew without providing a reason. After the 3-month treatment, the concentration of serum Ca, P, and the total AKP activities in the two groups remained within normal ranges.
Discussion
Many studies have shown that 40% to 100% of elderly people in the US and Europe suffer from vitamin D deficiencies [18, 19] . More than 50% of postmenopausal women had levels of 25-hydroxyvitamin D that were lower than 30 ng per milliliter [19] . Low levels of 25(OH)D are associated with a significant decrease in the absorption of intestinal calcium and induced secondary hyperparathyroidism [18, 20] . Secondary hyperparathyroidism may stimulate the transformation of preosteoclasts into mature osteoclasts, causing osteoporosis and increasing the risk of fracture [19] . Our results show that serum Ca levels increased and serum PTH levels decreased significantly after supplementation with cholecalciferol (800 IU/d) plus Caltrate D for three months. Kuwabara et al [21] discovered that the supplementation of 200 mg of calcium with 800 IU of vitamin D 3 daily for one month significantly lowered the serum PTH levels compared with the supplementation of only 200 mg of calcium daily. Seemans et al [17] identified that in the winter, the endpoint serum PTH level to be significantly lower in 3 cholecalciferol-supplemented groups (cholecalciferol 200 IU, 400 IU, and 600 IU) compared with the placebo group, though other bone turnover markers were not affected. An increased rate of bone turnover is associated with low bone mass [22] and an increased risk of bone fracture [23] . Higher levels of serum CTX indicate an increase in bone resorption and bone fragility [24] . Total AKP is primarily a nonspecific marker of bone formation. Our results show that after supplementing with 800 IU per day of cholecalciferol for three months, serum AKP levels increased significantly, and serum β-CTX levels decreased. These results indicate that 800 IU per day of cholecalciferol is effective for stimulating bone formation and reducing bone resorption. Hurst et al [16] has shown that vitamin D-deficient women who were administered 4000 IU of cholecalciferol daily for 6 months displayed a suppression of age-induced bone turnover and bone resorption. However, some studies have shown cholecalciferol supplementation have no effect on bone turnover markers [17, 21] . Oral vitamin D supplementation increases bone mineral density and appears to reduce the risk of hip and other nonvertebral fractures. Therefore, it is reasonable to supply 800-1000 IU/d of vitamin D to older individuals [25] . Heaney et al [11] found that after supplementing with 1000, 5000, and 10 000 IU of cholecalciferol, the serum 25(OH)D levels of every group plateaued after 3-4 months intervention. Therefore, Hanley et al [9] suggested measuring the serum 25(OH)D after 3-4 months of adequate intervention. In our study, the mean concentration of serum 25(OH)D increased from 16.01 to 20.02 ng/mL after 3 months of supplementation with cholecalciferol. However, 49% of this group was still vitamin D-deficient. The cholecalciferol group in our study was provided with 125 IU of Caltrate D. Therefore, the total cholecalciferol reached 925 IU, and the dose was not sufficient to achieve adequate 25(OH)D concentrations. Similarly, Pignotti et al [26] have shown that after supplementation with 400 IU of cholecalciferol and 1200 mg of calcium for 3 months in sunny Brazil, the concentration of serum 25(OH)D increased from 18.7 ng/mL to 23.8 ng/mL. However, 86.2% of the supplemented group did not reach optimal levels (30.0 ng/mL) of 25(OH)D. Kuwabara et al [21] discovered that after supplementation with 800 IU of cholecalciferol and 200 mg of calcium for 1 month, serum 25(OH)D levels in old men and women increased from 9.7 ng/mL to 19.3 ng/mL, although 60% of the subjects remained vitamin D-deficient. However, Chapuy et al [27] reported that after supplementation with 800 IU of cholecalciferol and 1200 mg of calcium for 6 months, serum 25(OH)D levels increased from 9.2 ng/mL to 30.0 ng/mL. The varied results of these different studies may be associated with the dose of cholecalciferol, the period of study, the intake of calcium and differences associated with the population. Hanley et al [9] systematically reviewed 168 potentially relevant vitamin D papers from 1996 to 2008 and concluded that vitamin D was necessary for the prevention of osteoporosis. They recommended an intake of cholecalciferol for high-risk and older adults ranging from 800 to 2000 IU daily. To achieve satisfactory vitamin D status (>30 ng/mL), many individuals may require higher doses. A similar suggestion was made at an expert roundtable discus- [10] . In addition, this recommendation was independent of sun exposure, seasonal exposure and additional multivitamin use.
Calcitriol has been used as a therapy for osteoporosis for many years. One study verified that supplementation with calcitriol at 0.5 µg per day for six months may promote bone formation and decrease bone absorption [28] . Active vitamin D analogs have a larger impact in decreasing bone loss and fracture incidence than standard vitamin D in postmenopausal osteoporosis because vitamin D analogs display a greater effect in reducing numbers of falls [29] . Calcitriol plays an important role in skeletal system regulation and may have other bone-protective effects independent of its calcium absorption effects [30] . To prevent hypercalcinuria, patients with osteoporosis or osteopenia in China are frequently treated with 0.25 μg/d of calcitriol [13] . After 3 months of intervention in our study, no differences were identified in calcium metabolism and bone turnover between the group treated with 0.25 µg of calcitriol daily and the group treated with 800 IU of cholecalciferol daily. Serum calcium and AKP levels were significantly increased in both groups. The serum PTH and β-CTX levels were significantly decreased in both groups. However, the serum 25(OH)D level did not change significantly in the calcitriol group; it showed only a slight decreasing trend. Clements et al [31] discovered that after supplementation with 1 µg per day of calcitriol to treat postmenopausal osteoporosis, hypoparathyroidism and hypophosphatemic osteomalacia, the elimination half-time for 25(OH)D in the plasma could be significantly shortened by raising the circulating concentration of 1,25-dihydroxyvitamin D. One explanation for this result is that calcitriol is the activated form of cholecalciferol, and excessive calcitriol decreases serum 25(OH) in a negative feedback system. Halloran et al [32] discovered that rats chronically administered calcitriol displayed reduced serum concentrations of 25-OH-D 3 and 24,25(OH) 2 D 3 in a dose-and timedependent fashion. Calcitriol administration increased the metabolic clearance of 25-OH-D but not its production.
After 3 months of intervention, the concentration of serum Ca, P, and the total AKP activities in both groups remained within normal ranges. However, urinary calcium excretions were not observed in either group; this was a limitation of our study. In the United States, the previous NOF guidelines set the safe upper limit for vitamin D intake at 2000 IU per day. However, recent evidence has shown that higher intake is safe and that some older patients need at least this amount to maintain adequate 25(OH)D levels [8] . Doses of more than 50 000 IU of vitamin D 3 per day are associated with hypercalcemia and hyperphosphatemia [33] . However, Vieth et al [34] observed that doses of 10 000 IU of cholecalciferol daily for up to 5 months did not cause toxicity. In a randomized, double-blind trial that tested the efficacy and safety of zoledronic acid (5 mg) that was intravenously supplemented annually in preventing new fractures in women and men who had hip fractures [35] , all the patients received oral calcium (1000-1500 mg) and vitamin D (800-1200 IU) daily. By the end of the study, none of the patients suffered from hypercalcemia. These results indicate that the current safe upper intake level of 2000 IU of vitamin D per day may be too conservative.
Our current study indicated that that cholecalciferol (800 IU/d) plus Caltrate D increased the mean serum 25(OH)D to 20 ng/mL in most but not all individuals. Both 800 IU/day of cholecalciferol and 0.25 μg/day of calcitriol plus Caltrate D effectively modified calcium and bone turnover markers in postmenopausal women in Shanghai with vitamin D insufficiency. The use cholecalciferol or calcitriol and the doses specified in the study for improving the bone health of postmenopausal women requires further investigation.
